A randomised, open-label, parallel group study to compare the pharmacokinetics and pharmacodynamics of NEODIDRO® 0.266 mg vs DIBASE® 25,000 IU oral doses in male and female patients.
CRC2024_01
Phase 1 other active
Quick answer
A randomised, open-label, parallel group study to compare the pharmacokinetics and pharmacodynamics of NEODIDRO® 0.266 mg vs DIBASE® 25,000 IU oral doses in male and female patients. for Patients with low Vitamin D plasma level is a Phase 1 program (other) at Verona Pharma Ireland Limited with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Verona Pharma Ireland Limited
- Indication
- Patients with low Vitamin D plasma level
- Phase
- Phase 1
- Modality
- other
- Status
- active